25 May 2013
Keywords: ablynx, deal, novartis, extended, bi, milestone, ghent
Article | 16 February 2009
Ghent, Belgium-based Ablynx, a pioneer in the discovery and development of Nanobodies, a novel class of antibody-derived therapeutic proteins,
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
16 February 2009
24 May 2013
© 2013 thepharmaletter.com